LONG-TERM RESULTS OF THE MULTICENTER PHASE II TRIAL WITH BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT FOR PATIENTS WITH MALT LYMPHOMA (MALT-2008-01).
Salar, A., Domingo-Domenech, E., Panizo, C., Nicolás, C., Bargay, J., Muntañola, A., Canales, M., Bello, J., Sancho, J., Tomás, J., Rodriguez, M., Peñalver, F.J., Palomera, L., Grande, C., Sánchez-BlaVolume:
35
Language:
english
Journal:
Hematological Oncology
DOI:
10.1002/hon.2437_137
Date:
June, 2017
File:
PDF, 88 KB
english, 2017